Pharus Sicav Biotech changes its name to Pharus Sicav Medical Innovation
The fund, focused on companies operating in the biotechnology sector and at the forefront in the field of medical innovation, changed its name from December 1, 2020, in order to better distinguish its strategy from that of traditional Biotech sub-funds.
The fund's strategy is to select companies active both in the research of innovative drugs based on the most advanced biotechnologies and in possession of interesting technologies that could be used for the development of innovative therapies, applicable to various areas including the health care industry. The fund also focuses on small and medium-sized companies, which invest more in research and development, and which are meant to be the protagonists of medical innovation.
Hence the name Pharus Sicav Medical Innovation: Pharus focuses on those highly innovative companies in the biotechnology field that carry out pharmaceutical research and which will potentially become the leaders of tomorrow.
The contents of this informative message are the result of the free interpretation, evaluation and appreciation of Pharus Asset Management SA and constitute simple food for thought.
Any information and data indicated have a purely informative purpose and do not in any way represent an investment advisory service: the resulting operational decisions are to be considered taken by the user in full autonomy and at his own exclusive risk.
Pharus Asset Management SA dedicates the utmost attention and precision to the information contained in this message; nevertheless, no liability shall be accepted for errors, omissions, inaccuracies or manipulations by third parties on what is materially processed capable of affecting the correctness of the information provided and the reliability of the same, as well as for any result obtained using the said information.
It is not permitted to copy, alter, distribute, publish or use these contents on other sites for commercial use without the specific authorization of Pharus Asset Management SA.